The forecast for Measles-Containing-Vaccine Second-Dose (MCV2) immunization coverage in China from 2024 to 2028 remains consistently high at 99% for children of the nationally recommended age. This follows the actual coverage of 99% in 2023, indicating no year-on-year variation and a stable coverage rate. The Compound Annual Growth Rate (CAGR) over the last five years remains 0% due to the unchanged coverage rate. This stability suggests that China has effectively reached near-maximal immunization coverage for MCV2.

Future trends to watch for include:

Potential policy shifts towards maintaining or increasing coverage amidst demographic changes.
Monitoring vaccine hesitancy or public health challenges that could impact future coverage rates.
Innovations in vaccine distribution that might affect service delivery efficiency.